Richard Bruce Silverman

Richard Bruce Silverman (born May 12, 1946) is the Patrick G. Ryan/Aon Professor of Chemistry at Northwestern University.

His group's main focus is basic and translational research into central nervous system disorders and cancer.

He is known for the discovery of pregabalin, which is marketed by Pfizer under the brand name Lyrica.

Silverman attended Central High School of Philadelphia.

Silverman received his B.S. in chemistry from Pennsylvania State University in 1968.

He spent one semester at Harvard University before being drafted and serving as a United States Army Physical Sciences Assistant at the Walter Reed Army Institute of Research from January 1969 until his honorable discharge in January 1971.

In June 1974, he received his Ph.D. from Harvard University in organic chemistry with advisor David Dolphin.

He then spent two years as a postdoctoral fellow with Robert Abeles in biochemistry at Brandeis University.

Silverman has been teaching and doing research at Northwestern since 1976.

He became both professor of chemistry and professor of biochemistry, molecular biology, and cell biology in 1986.

He has held several named professorships.

He was the Arthur Andersen Professor of Chemistry from 1988 to 1996, the Charles Deering McCormick Professor of Teaching Excellence from 2001 to 2003, and the John Evans Professor of Chemistry beginning from 2004 to 2015.

He has written 3 books (one in the third edition): Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology (CRC Press; 1988), Organic Chemistry of Drug Design and Drug Action (Academic Press; 1992, 2004, 2014), and Organic Chemistry of Enzyme-Catalyzed Reactions (Academic Press; 2000, 2002; see the Published works section, below).

He is active on the editorial boards of a number of scholarly journals.

Silverman is known for inventing the drug pregabalin as a possible treatment for epileptic seizures.

During 1988-1990, Ryszard Andruszkiewicz, a visiting research fellow, synthesized a series of molecules for Silverman.

One looked promising.

The molecule was transported into the brain, where it activated the enzyme L-glutamate decarboxylase.

Silverman anticipated that the enzyme would increase production of the inhibitory neurotransmitter GABA and block convulsions.

Eventually, the set of molecules were sent to Parke-Davis Pharmaceuticals for testing.

In addition to treating seizures, pregabalin was found to be effective in treating fibromyalgia pain, neuropathic pain, and generalized anxiety disorder.

It was approved by the FDA in 2004 and marketed by Pfizer (which bought Parke-Davis) under the trade name Lyrica.

Research has shown that the mechanism of the drug is more complicated than originally anticipated.

In addition to its effects on GABA-AT substrate behavior, pregabalin binds to calcium channels and blocks glutamate release.

GABA is potentiated, but through a different mechanism than originally suspected.

Silverman has received numerous teaching awards from Northwestern University, including the following:

Lyrica royalties paid to Northwestern, and a gift from Silverman himself, have supported the Silverman Hall for Molecular Therapeutics and Diagnostics at Northwestern University.

Silverman Hall, which opened in 2009, was designed to be a collaborative and interdisciplinary facility housing researchers from chemistry, biology, and engineering.

He was named the inaugural Patrick G. Ryan/Aon Professor as of September 1, 2015.

The primary focus in Silverman's laboratory is basic research into central nervous system disorders, including Amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, and epilepsy.

Other research areas include cancer (melanoma and hepatocellular carcinoma).

He has developed novel approaches to the elucidation of enzyme-catalyzed reactions in organic chemistry.

He is interested in understanding and developing mechanisms of enzyme inhibition.

Silverman has published about 400 research articles.

He has been awarded 130 patents.